Frailty is a common condition in adults over 70: weight loss, general weakness, slow walking, and constant fatigue. To date, there is no specific treatment. Only nutritional counseling and physical therapy. But a new study published in Cell Stem Cell by Longeveron presents a breakthrough: Treatment with mesenchymal stem cells significantly improved the physical function of patients with frailty.
The Trial
The team recruited 148 ambulatory elderly individuals (i.e., able to walk on their own) aged 70 to 85 diagnosed with frailty. This was a dose-escalation trial: participants were divided into a placebo group and several treatment groups with different doses of stem cells (25, 50, 100, and 200 million cells), and received a single intravenous injection of allogeneic mesenchymal stem cells (donated from the bone marrow of healthy donors). These cells, called laromestrocel (also known as Lomecel-B), are cells that can suppress inflammation and support tissues.
Results After 9 Months
The team measured physical ability using the 6-minute walk test (6MWT), a standard test in geriatrics. The improvement was dose-dependent: the higher the dose, the greater the improvement, and the high-dose group (200 million cells) showed the most notable result:
- The high-dose group (200 million cells) showed an improvement of 63.4 meters in walking during 6 minutes compared to placebo, after 9 months
- The control group (placebo) showed negligible improvement
- 30.8% of patients changed from frail status to non-frail status
This difference is not just statistical. 63 meters in 6 minutes is the difference between someone who can go down and up a flight of stairs and someone who cannot. It is the difference between independence and dependence.
How Does It Work?
Allogeneic mesenchymal stem cells act through several parallel mechanisms. In this trial, researchers attributed the effect mainly to vascular-supporting activity and anti-inflammatory effects:
- Suppression of inflammaging. They secrete anti-inflammatory factors that reduce the chronic inflammatory background characteristic of aging
- Repair of vascular function. They support blood vessel function, which can improve oxygen flow to muscles. The trial even identified a biomarker related to vascular function (TIE2) that changed in a dose-dependent manner
- Regenerative support. MSC cells release factors that support tissue repair and maintenance
It is important to note: additional mechanisms sometimes attributed to MSC cells in general (e.g., hormonal signaling or activation of satellite cells in muscle) were not measured or reported in this specific trial, and should not be considered its findings.
The Advantage of "Allogeneic"
"Allogeneic" means the stem cells come from a donor's bone marrow, not from the patient themselves. This is a major advantage in terms of availability: the treatment can be produced in advance and used for a wide range of patients. There is no need to wait for personalized processing. Additionally, MSC cells are considered "immune-privileged," meaning they tend to provoke less rejection response.
What's Next?
The company plans a larger Phase 3 trial. If the results are maintained and confirmed in a large, controlled trial, laromestrocel could in the future become a treatment specifically targeting geriatric frailty. However, independent experts urge caution: these are early Phase 2b results, and confirmation in Phase 3 is needed before firm conclusions. Meanwhile, several companies (mainly in the US, Japan, and Korea) offer similar treatments outside regulatory clinics. Researchers warn: Stem cell treatments are only approved in clinical trials. Any commercial treatment is considered unapproved and can be dangerous.
The Bottom Line
This is a Phase 2b trial showing encouraging results: stem cell treatment significantly improved physical function in elderly individuals with frailty, and 30.8% of patients transitioned from frail to non-frail status. This is still an improvement, not a confirmed reversal of the process, and confirmation in Phase 3 is needed. It is an interesting step toward active aging: not just living more years, but living them with strength and normal function.
💬 Comments (0)
Be the first to comment on the article.